Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
The results form a prospective multicentre study provide a rationale for designing ctDNA-based risk-adaptive CAR T-cell clinical studies
EMA’s Pharmacovigilance Risk Assessment Committee concluded review of a safety signal
The results of the ECOG-ACRIN EA1131 study in basal subtype triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
Avapritinib, a kinase inhibitor, was evaluated in the EXPLORER and PATHFINDER studies
Targeting unmet need in EGFR tyrosine kinase inhibitor resistant non-small cell lung cancer
Pivotal results of the phase II, ZUMA-3 study
Data support metronomic capecitabine as a potential adjuvant therapy for nasopharyngeal carcinoma
A novel checkpoint inhibitors combination of nivolumab plus relatlimab validate dual LAG-3 and PD-1 inhibition
New indications concern the treatment of patients with multiple myeloma and light chain amyloidosis
New indication concerns the treatment of paediatric patients with high-risk first relapsed Philadelphia chromosome negative CD19-positive B-precursor ALL
Findings from the eNRGy1 global multicentre registry
The results of the CheckMate 274 study point to first immune checkpoint inhibitor prolonging the disease-free survival in this setting
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
